Start Date
May 1, 2024
Primary Completion Date
June 30, 2025
Study Completion Date
August 31, 2025
ADV7103
Patients receive ADV7103 twice a day at optimal dose.
Standard of Care
Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
CHU Pitié-Salpétrière, Paris
CHU Purpan, Toulouse
CHU de Bordeaux - Hôpital Pellegrin, Bordeaux
CHU Grenoble, Grenoble
Hôpital Américain CHU de Reims, Reims
CHU Reims, Reims
CHRU Lille, Lille
Centre Hospitalier Universitaire de Lyon, Bron
Hôpital Necker AP-HP, Paris
Hôpital Necker Enfants Malades, Paris
Hôpital Ténon - Explorations fonctionnelles Mutlidisciplinaires et INSERM UMR S 1155, Paris
Cliniques Universitaires Saint-Luc, Brussels
UZ Leuven, Gasthuisberg Hospital, Leuven
Lead Sponsor
Advicenne Pharma
INDUSTRY